Please login to the form below

Not currently logged in
Email:
Password:

tralokinumab

This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.

AZ’s Fasenra hit by COPD trial failure

AZ’s Fasenra hit by COPD trial failure

IL-13 inhibitor tralokinumab has been abandoned after three failed late-stage trials, however, while AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase III

Latest news

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Leo has its eyes on the prize Leo has its eyes on the prize

    Its landmark partnership with AstraZeneca and the launch of Kyntheum, the fully-human monoclonal antibody targeting psoriasis, and the phase III hope of tralokinumab for atopic dermatitis are part of an

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.

  • Deal Watch July 2016 Deal Watch July 2016

    AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics